Oramed Announces Positive Initial Clinical Trial Results for Treatment of NASH With Oral Insulin

Data Presented at the American Diabetes Association Scientific Session 2020 NEW YORK, June 15, 2020 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that its pilot study of its oral insulin candidate ORMD-0801 in type 2 diabetes patients with non-alcoholic […]

Join our mailing list

Skip to content